MedPath

Lercanidipine

Generic Name
Lercanidipine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C36H41N3O6
CAS Number
100427-26-7
Unique Ingredient Identifier
V7XTJ4R0BH
Background

Lercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.

Indication

For the treatment of Hypertension, management of angina pectoris and Raynaud's syndrome

Associated Conditions
Hypertension, Mild Hypertension, Moderate Essential Hypertension
Associated Therapies
-
Clinical Trials
Related News

Bariatric Surgery and Pharmacokinetics of Lercanidipine

Recruiting
Conditions
Obesity, Morbid
First Posted Date
2018-04-13
Last Posted Date
2023-05-10
Lead Sponsor
Norwegian University of Science and Technology
Target Recruit Count
12
Registration Number
NCT03497156
Locations
🇳🇴

St. Olavs University Hospital, Trondheim, Norway

Zainidip in Renal Artery Stenosis

Phase 4
Completed
Conditions
Hypertension
Interventions
Device: stent
Drug: Aspirine
Drug: Clopidogrel
Drug: Lercanidipine
First Posted Date
2015-11-03
Last Posted Date
2015-11-03
Lead Sponsor
Lee's Pharmaceutical Limited
Target Recruit Count
149
Registration Number
NCT02594410
Locations
🇨🇳

Fuwai Hospital, Beijing, China

Intensive Vasodilator Therapy in Patients With Essential Hypertension

Phase 4
Completed
Conditions
High Blood Pressure
Essential Hypertension
Interventions
Drug: Amlodipine
Drug: Ramipril
Drug: Lercanidipine
Drug: Losartan
First Posted Date
2010-08-12
Last Posted Date
2012-04-19
Lead Sponsor
Aarhus University Hospital
Target Recruit Count
48
Registration Number
NCT01180413
Locations
🇩🇰

Aarhus University Hospital - dept. cardiology (A), Aarhus, Denmark

Efficacy and Safety of Lercanidipine and Enalapril in Patients With Essential Hypertension

Phase 2
Completed
Conditions
Essential Hypertension
Interventions
Drug: Lercanidipine + Enalapril
Drug: Placebo
Drug: Lercanidipine
Drug: Enalapril
First Posted Date
2010-03-26
Last Posted Date
2011-04-29
Lead Sponsor
RECORDATI GROUP
Target Recruit Count
1039
Registration Number
NCT01093807
Locations
🇫🇷

Hôpital de la Pitié-Salpétrière, Paris, France

Effects of Antihypertensive Treatment in HIV Infected Patients: Candesartan Versus Lercanidipine

Phase 4
Conditions
Hypertension
HIV Infections
Interventions
Drug: candesartan
Drug: lercanidipine
First Posted Date
2007-11-27
Last Posted Date
2007-12-06
Lead Sponsor
Università degli Studi dell'Insubria
Target Recruit Count
30
Registration Number
NCT00564057
Locations
🇮🇹

University of Insubria, Department of Clinical Medicine, Varese, Italy

Effects of Intensive Long-Term Vasodilation in Hypertensive Patients With Microvascular Angina Pectoris

Not Applicable
Terminated
Conditions
Microvascular Angina
Hypertension
Interventions
Drug: Lercanidipine
Drug: Valsartan
Drug: Nicorandil
Drug: Doxazosin
Drug: Moxonidin
Drug: Pindolol
Drug: Amiloride, hydrochlorothiazide
First Posted Date
2007-01-22
Last Posted Date
2009-05-06
Lead Sponsor
University of Aarhus
Target Recruit Count
10
Registration Number
NCT00424801
Locations
🇩🇰

Aarhus Hospital, Aarhus, Denmark

Testing the Efficacy of Different Dosages of Lercanidipine to Reduce Hypertensive Blood Pressure in Normal Weight and Obese Patients

Not Applicable
Completed
Conditions
Hypertension
First Posted Date
2005-09-12
Last Posted Date
2008-03-10
Lead Sponsor
UCB Pharma
Target Recruit Count
180
Registration Number
NCT00160498
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy